Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 587

1.

The evolving role of dabigatran etexilate in clinical practice.

Hellenbart E, Drambarean B, Lee J, Nutescu EA.

Expert Opin Pharmacother. 2015 Sep;16(13):2053-72. Epub 2015 Aug 6.

PMID:
26245513
2.

Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.

Couturaud F, Sanchez O, Pernod G, Mismetti P, Jego P, Duhamel E, Provost K, dit Sollier CB, Presles E, Castellant P, Parent F, Salaun PY, Bressollette L, Nonent M, Lorillon P, Girard P, Lacut K, Guégan M, Bosson JL, Laporte S, Leroyer C, Décousus H, Meyer G, Mottier D; PADIS-PE Investigators.

JAMA. 2015 Jul 7;314(1):31-40. doi: 10.1001/jama.2015.7046.

PMID:
26151264
3.

The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.

Gonda DD, Fridley J, Ryan SL, Briceño V, Lam SK, Mba MD, Luerssen TG, Jea A.

J Neurosurg Pediatr. 2015 Jun 12:1-6. [Epub ahead of print]

PMID:
26067336
4.

Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis.

Chai-Adisaksopha C, Hillis C, Monreal M, Witt DM, Crowther M.

Thromb Haemost. 2015 May 28;114(4). [Epub ahead of print]

PMID:
26018236
5.

Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.

Gehrie E, Tormey C.

Arch Pathol Lab Med. 2015 May;139(5):687-92. doi: 10.5858/arpa.2013-0677-RS. Review.

PMID:
25927153
6.

Dabigatran for the prevention and treatment of thromboembolic disorders.

Enriquez A, Baranchuk A, Redfearn D, Simpson C, Abdollah H, Michael K.

Expert Rev Cardiovasc Ther. 2015 May;13(5):529-40. doi: 10.1586/14779072.2015.1034692. Epub 2015 Apr 5.

PMID:
25843430
7.

Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation.

Shields AM, Lip GY.

J Intern Med. 2015 Jul;278(1):1-18. doi: 10.1111/joim.12360. Epub 2015 Apr 15. Review.

PMID:
25758241
8.

Safety and efficacy of target-specific anticoagulants in patients with venous thromboembolism.

Lekura J.

Ann Pharmacother. 2015 Apr;49(4):448-57. doi: 10.1177/1060028014568550. Epub 2015 Jan 22. Review.

PMID:
25614527
9.

The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.

Sengupta N, Feuerstein JD, Patwardhan VR, Tapper EB, Ketwaroo GA, Thaker AM, Leffler DA.

Am J Gastroenterol. 2015 Feb;110(2):328-35. doi: 10.1038/ajg.2014.398. Epub 2014 Dec 16. Erratum in: Am J Gastroenterol. 2015 Mar;110(3):480.

PMID:
25512338
10.

Evaluation of postextraction bleeding incidence to compare patients receiving and not receiving warfarin therapy: a cross-sectional, multicentre, observational study.

Iwabuchi H, Imai Y, Asanami S, Shirakawa M, Yamane GY, Ogiuchi H, Kurashina K, Miyata M, Nakao H, Imai H.

BMJ Open. 2014 Dec 15;4(12):e005777. doi: 10.1136/bmjopen-2014-005777.

11.

Target intensity of anticoagulation with warfarin in Japanese patients with valvular atrial fibrillation – subanalysis of the J-RHYTHM Registry.

Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T; J-RHYTHM Registry Investigators.

Circ J. 2015;79(2):325-30. doi: 10.1253/circj.CJ-14-1057. Epub 2014 Dec 10.

12.

Parenteral anticoagulation in ambulatory patients with cancer.

Akl EA, Kahale LA, Ballout RA, Barba M, Yosuico VE, van Doormaal FF, Middeldorp S, Bryant A, Schünemann H.

Cochrane Database Syst Rev. 2014 Dec 10;12:CD006652. doi: 10.1002/14651858.CD006652.pub4. Review.

PMID:
25491949
13.

[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].

Beliavskaia OO, Vavilova TV.

Angiol Sosud Khir. 2014;20(4):37-41. Russian.

PMID:
25490355
14.

Venous thromboembolism in cancer patients.

Deng A, Galanis T, Graham MG.

Hosp Pract (1995). 2014 Dec;42(5):24-33. doi: 10.3810/hp.2014.12.1156. Review.

PMID:
25485915
15.

Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts).

Ashburner JM, Go AS, Reynolds K, Chang Y, Fang MC, Fredman L, Applebaum KM, Singer DE.

Am J Cardiol. 2015 Jan 1;115(1):40-6. doi: 10.1016/j.amjcard.2014.10.006. Epub 2014 Oct 12.

PMID:
25456871
16.

Antithrombotic and anticoagulant therapy for atrial fibrillation.

Dzeshka MS, Lip GY.

Cardiol Clin. 2014 Nov;32(4):585-99. doi: 10.1016/j.ccl.2014.07.009. Epub 2014 Sep 2. Review.

PMID:
25443239
17.

Monitoring and reversal strategies for new oral anticoagulants.

Vanden Daelen S, Peetermans M, Vanassche T, Verhamme P, Vandermeulen E.

Expert Rev Cardiovasc Ther. 2015 Jan;13(1):95-103. doi: 10.1586/14779072.2015.987126. Epub 2014 Nov 28.

PMID:
25431993
18.

A case of cerebral venous sinus thrombosis associated with Crohn's disease: dilemma in management.

Kwon Y, Koene RJ, Cho Y.

Gastroenterol Rep (Oxf). 2014 Nov 10. pii: gou079. [Epub ahead of print]

19.
20.

Bridging therapy in antiphospholipid syndrome and antiphospholipid antibodies carriers: case series and review of the literature.

Raso S, Sciascia S, Kuzenko A, Castagno I, Marozio L, Bertero MT.

Autoimmun Rev. 2015 Jan;14(1):36-42. doi: 10.1016/j.autrev.2014.09.002. Epub 2014 Sep 18. Review.

PMID:
25242343
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk